All treatments
Treatment
Placebo to match CHF6001 DPI clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomized, double-blind, placebo-controlled, parallel-group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.
This study is looking at a new medicine called CHF6001. It's for people with COPD and chronic bronchitis who are already using a 3-in-1 inhaler. We want to see if adding CHF6001 helps reduce flare-ups and improve breathing and quality of life over a year.
For: Chronic obstructive pulmonary disease (COPD) and Chronic BronchitisHungary · Germany · Slovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500μg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis
This study looks at new inhaled medications for people with a type of lung disease called COPD. It aims to see if these new medicines can help reduce flare-ups, improve breathing, and make everyday life better.
For: Chronic Obstructive Pulmonary Disease (COPD)Spain · Estonia · Austria